Witjes - Figure 40
Immuno/combinations in high-risk patients
FIG. 40: A conclusion similar to the one from FinnBladder-4[24] (Figure 39) can be drawn from the FinnBladder-6 study, which compared BCG with the combination of epirubicin plus IFN-α2a.[25] The study included a maintenance schedule in 230 patients, and although progression rates were similar, again, BCG was significantly more effective with respect to recurrence rates over long-term follow-up. So this appears to be the answer for use of all the combinations with interferon.
References
Järvinen R, Marttila T, Kaasinen E, et al; FinnBladder Group. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study. Eur Urol. 2015;68:611−7 http://dx.doi.org/10.1016/j.eururo.2015.02.022
Marttila T, Järvinen R, Liukkonen T, et al. Intravesical bacillus Calmette-Guérin versus combination of epirubicin and interferon-α2a in reducing recurrence of non-muscle-invasive bladder carcinoma: FinnBladder-6 study. Eur Urol. 2016;70:341−7 http://dx.doi.org/10.1016/j.eururo.2016.03.034
